Telix, Grupo RPH ink production & distribution agreement in Brazil
Category: #health  By Mateen Dalal  Date: 2019-07-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Telix, Grupo RPH ink production & distribution agreement in Brazil

The agreement gives Grupo RPH exclusive right to manufacture and distribute the TLX591-Cdx in the Latin American market

Clinical-stage biopharmaceutical firm Telix Pharmaceutical has reportedly signed a manufacturing and distribution agreement with Grupo RPH.

Grupo RPH will become the contract manufacturer as well as distributor for Telix in Brazil. According to an official statement, their initial focus as partners will be on TLX591-CDx (68Ga-PSMA-11) for prostate cancer imaging, but the contract agreement is built so as to allow Telix to include other products as well later on.

Rafael Madke, Grupo RPH Managing Director stated that Telix’s rapid expansion over the past year has been remarkable, and with Grupo RPH holding the upper hand in the Brazilian market owing to its proficiency to fabricate and distribute radiopharmaceuticals, the company will be able to support Telix’s commercial goals cost-effectively.

Telix Vice President for Corporate Development, Ludovic Wouters was quoted saying that the alliance offers their gallium-68 based nuclear medicinal products a massive and rapidly growing market. He further added they were looking forward to working with Grupo RPH to introduce their prostate cancer imaging technology into the Latin American market.

For the uninitiated, Telix Pharmaceuticals Limited is a global clinical-stage biopharmaceutical corporation aimed at the development of therapeutic and diagnostic radiopharmaceutical products based on molecularly targeted radiation (MTR). The Melbourne-headquartered company has international businesses in Indianapolis (US), Brussels (UK), and Kyoto (Japan).

Supposedly, the company is aiming to develop a portfolio of clinical-stage oncology offerings which can tackle numerous unmet needs of patients with prostate, renal and brain cancer.

Grupo RPH commercially offers 8 different Cold Kits for Ga68 and Tc99m manufacturing in the Brazilian market. The firm also owns the GMP manufacturing facility based in Brazil for radiopharmaceutical products and exports its products throughout the country for serving more than 400 customers every day. The company is also known to have pioneered Brazil’s centralized radio-pharmacy model.

 

Source credit: https://www.globenewswire.com/news-release/2019/07/03/1877635/0/en/Telix-Pharmaceuticals-and-Grupo-RPH-Sign-LATAM-Manufacturing-and-Distribution-Agreement.html?print=1

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...

Verrica unveils positive data from VP-102 study in molluscum treatment
Verrica unveils positive data from VP-102 study in molluscum treatment
By Mateen Dalal

Findings from the study are being produced at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast The data indicated a considerable increase in the percentage of patients with lesion clearance in VP-102 group Verrica Pharmaceu...